JGC
MLTX icon

J. Goldman & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

J. Goldman & Co’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$527K – 797
2025
Q4 		$527K Buy
+40,000
New +$472K 0.01% 448

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Goldman & Co's MLTX Position: Q2 2026 in Review

J. Goldman & Co increased its MoonLake Immunotherapeutics (MLTX) stake by 58% in Q2 2026, buying an estimated $1.43M and bringing the position to 215,945 shares worth $4.2M. The position accounts for 0.11% of the portfolio, ranked #228.

J. Goldman & Co first reported a position in MLTX in Q1 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • J. Goldman & Co held 215,945 shares of MoonLake Immunotherapeutics worth $4.2M as of Q2 2026.
  • J. Goldman & Co bought 79,045 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.43M.
  • MoonLake Immunotherapeutics made up 0.11% of J. Goldman & Co's portfolio in Q2 2026, its #228 holding.
  • J. Goldman & Co first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.